WCG
EW icon

Weaver Consulting Group’s Edwards Lifesciences EW Stock Holding History

Weaver Consulting Group’s Portfolio EW Stock Details EW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.25M Sell
47,015
-234
-0.5% -$19.6K 0.87% 31
2026
Q1 		$3.78M Sell
47,249
-318
-0.7% -$26.2K 0.9% 28
2025
Q4 		$4.06M Buy
47,567
+1,198
+3% +$98.3K 0.99% 26
2025
Q3 		$3.61M Sell
46,369
-10
-0% -$781 0.92% 30
2025
Q2 		$3.63M Sell
46,379
-206
-0.4% -$15.4K 1% 28
2025
Q1 		$3.38M Sell
46,585
-350
-0.7% -$25.1K 1.02% 24
2024
Q4 		$3.47M Sell
46,935
-558
-1% -$39.1K 1.07% 23
2024
Q3 		$3.13M Sell
47,493
-359
-0.8% -$26.1K 1% 26
2024
Q2 		$4.42M Buy
47,852
+8,400
+21% +$744K 1.54% 15
2024
Q1 		$3.77M Sell
39,452
-1,000
-2% -$84K 1.4% 17
2023
Q4 		$3.08M Sell
40,452
-2,185
-5% -$152K 1.25% 20
2023
Q3 		$2.95M Buy
42,637
+1,524
+4% +$122K 1.33% 18
2023
Q2 		$3.88M Sell
41,113
-2
-0% -$174 1.71% 13
2023
Q1 		$3.4M Sell
41,115
-1
-0% -$79 1.56% 14
2022
Q4 		$3.07M Buy
41,116
+1,566
+4% +$121K 1.57% 13
2022
Q3 		$3.27M Buy
39,550
+76
+0.2% +$7.31K 1.88% 12
2022
Q2 		$3.75M Buy
39,474
+549
+1% +$56.8K 2.1% 10
2022
Q1 		$4.58M Buy
38,925
+200
+0.5% +$22.4K 2.22% 10
2021
Q4 		$5.02M Buy
38,725
+3
+0% +$350 2.42% 10
2021
Q3 		$4.38M Buy
38,722
+118
+0.3% +$13.5K 2.38% 9
2021
Q2 		$4M Buy
38,604
+780
+2% +$73.5K 2.25% 9
2021
Q1 		$3.16M Buy
37,824
+1,494
+4% +$126K 1.94% 12
2020
Q4 		$3.31M Buy
36,330
+675
+2% +$56K 2.07% 11
2020
Q3 		$2.85M Buy
35,655
+1,575
+5% +$123K 1.64% 11
2020
Q2 		$2.35M Sell
34,080
-663
-2% -$47.1K 1.37% 16
2020
Q1 		$2.18M Buy
34,743
+639
+2% +$46.1K 1.43% 14
2019
Q4 		$2.5M Buy
34,104
+1,365
+4% +$107K 1.34% 17
2019
Q3 		$2.37M Hold
32,739
– – 1.25% 19
2019
Q2 		$2.02M Sell
32,739
-390
-1% -$23.6K 1.1% 19
2019
Q1 		$2.04M Buy
+33,129
New +$1.89M 0.58% 28

Other funds holding EW

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
DZ Bank
DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Weaver Consulting Group's EW Position: Q2 2026 in Review

Weaver Consulting Group reduced its Edwards Lifesciences (EW) stake by 0.5% in Q2 2026, selling an estimated $19.6K and leaving 47,015 shares worth $4.25M. The position accounts for 0.87% of the portfolio, ranked #31.

Weaver Consulting Group first reported a position in EW in Q1 2019 and has held it in 30 quarters since. The position peaked at $5.02M in Q4 2021. 1,333 funds tracked by Wall St. Rank hold EW as of Q2 2026.

  • Weaver Consulting Group held 47,015 shares of Edwards Lifesciences worth $4.25M as of Q2 2026.
  • Weaver Consulting Group sold 234 Edwards Lifesciences shares in Q2 2026, an estimated $19.6K.
  • Edwards Lifesciences made up 0.87% of Weaver Consulting Group's portfolio in Q2 2026, its #31 holding.
  • Weaver Consulting Group first reported a position in Edwards Lifesciences in Q1 2019 and has held it in 30 quarters since.
  • Weaver Consulting Group's Edwards Lifesciences position peaked at $5.02M in Q4 2021.
  • 1,333 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on Weaver Consulting Group's 13F filing for Q2 2026, filed 29 Jul 2026.